EPO and Neurodevelopmental abnormality: However these findings contrast the recent reports from the largest, and most robust RCT included in this analysis, which found that combined Epo and TH had no effect on the incidence of death or neurodevelopmental disability at 2–3 years of age, and furthermore increased the likelihood of having at least one serious adverse event compared to those treated with TH and a placebo (Wu et al., 2022).